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Rationale: Alzheimer’s disease (AD) is a debilitating disease with complex
pathophysiology. Amyloid beta (Aβ) (1-42) is a reliable model of AD that recapitulates
many aspects of human AD.
Objective: The intent of the present study was to investigate the neuroprotective
potential of Coenzyme Q10 (CoQ10) and its modulation by minocycline (microglial
inhibitor) against Aβ (1-42) induced cognitive dysfunction in rats.
Method: Intrahippocampal (i.h.) Aβ (1-42) (1 μg/μl; 4μl/site) were administered
followed by drug treatment with galantamine (2 mg/kg), CoQ10 (20 and 40 mg/kg),
minocycline (50 and 100 mg/kg) and their combinations for a period of 21 days. Various
neurobehavioral parameters followed by biochemical, acetylcholinesterase (AChE) level,
proinflammatory markers (TNF-α), mitochondrial respiratory enzyme complexes (I-IV)
and histopathological examinations were assessed.
Results: Aβ (1-42) administration significantly impaired cognitive performance in Morris
water maze (MWM) performance test, causes oxidative stress, raised AChE level,
caused neuroinflammation, mitochondrial dysfunction and histopathological alterations
as compared to sham treatment. Treatment with CoQ10 (20 and 40 mg/kg) and
minocycline (50 and 100 mg/kg) alone for 21 days significantly improved cognitive
performance as evidenced by reduced transfer latency and increased time spent in
target quadrant (TSTQ), reduced AChE activity, oxidative damage (reduced LPO, nitrite
level and restored SOD, catalase and GHS levels), TNF-α level, restored mitochondrial
respiratory enzyme complex (I, II, III, IV) activities and histopathological alterations as
compared to Aβ (1-42) treated animals. Further, combinations of minocycline (50 and
100 mg/kg) with CoQ10 (20 and 40 mg/kg) significantly modulates the protective effect
of CoQ10 dose dependently as compared to their effect alone.
Conclusion: The present study suggests that the neuroprotective effect of CoQ10
could be due to its microglia inhibitory mechanism along with its mitochondrial restoring
and anti-oxidant properties.
Keywords: Alzheimer’s disease, Aβ (1-42), coenzyme Q10, minocycline, mitochondrial dysfunction, oxidative
stress, neuroinflammation
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INTRODUCTION
Alzheimer’s disease (AD) is a slow growing neurodegenerative
disorder, caused signiﬁcant cognitive dysfunction worldwide
(Hampel et al., 2011). It causes progressive loss of mental,
behavioral, functional deﬁcits and ability to learn (Braak and
Del Tredici, 2012). Globally, it accounts for more than 36
million people worldwide suﬀering from this slow growing
deadly disease (Anand et al., 2014; Association, 2014). The
major pathological characteristics of AD include deposition of
amyloid plaques (senile plaques) and neuroﬁbrillary tangles
(NFTs) (Zhong et al., 2009; Kumar and Singh, 2015). The amyloid
plaques are primarily composed of amyloid beta (Aβ) (1-42)
peptide. This peptide aggregates to form dimers and oligomers
which are the principal toxic species that leads to neuronal death
(Christensen et al., 2008).
Mitochondria are the major source of energy as well as both
producers as well as targets of reactive oxygen species (ROSs),
responsible for oxidative damage (Turrens, 2003; Medeiros et al.,
2007; Reddy, 2007; Kumar and Dogra, 2009; Kumar and Singh,
2015). It has been reported that Aβ (1-42) administration causes
an impairment of mitochondrial energy metabolism in diﬀerent
regions of the brain, which leads to progressive deterioration
of mitochondrial functions, excessive free radical generation,
eventually results DNA damage and cell death (Lenaz et al., 1998;
Turrens, 2003; Reddy and Beal, 2005; Zeevalk et al., 2005; Reddy,
2007; Dumont and Beal, 2011; Federico et al., 2012; Kumar and
Singh, 2015).
Research studies demonstrated that the Aβ (1-42)
accumulation initiates a series of cellular cascades including
glial cell (microglia and astrocytes) activation (Lenaz et al.,
1998; Seabrook et al., 2006; Medeiros et al., 2007). The exact
mechanism behind Aβ induced neuroinﬂammation hypothesis
is still unknown (Seabrook et al., 2006). However, oxidative
damage and mitochondrial dysfunction are considered to be
responsible for shifting the cell signaling pathways toward
proinﬂammatory and pro-apoptotic signals creating a link
between oxidative stress and neuroinﬂammation (Rosales-Corral
et al., 2010).
Since oxidative stress, mitochondrial dysfunction and
neuroinﬂammation are all entailed in the pathogenesis of AD
treatment with antioxidants along with mitochondrial restoring
and anti-inﬂammatory property have been considered as one
of the therapeutic strategy for the management of cognitive
dysfunction including AD. Coenzyme Q10 (CoQ10) is a
lipophilic, endogenous, vitamin-like antioxidant compound
(Bentinger et al., 2010; Dumont et al., 2011). It has been reported
to improve cognition, restored mitochondrial function and
facilitates ATP synthesis (Beal, 2004; Turunen et al., 2004;
Ishrat et al., 2006; Bentinger et al., 2010). It has been further
reported that supplementation of CoQ10 increases endogenous
CoQ10 content in rat brain (Lenaz et al., 1998; Rauscher et al.,
2001; Somayajulu et al., 2005; Ishrat et al., 2006; Kim and Suh,
2009; Hargreaves, 2014). It also possesses membrane stabilizing
properties and provides neuroprotection in various models of
neurodegenerative disorders (Beal, 2004; Turunen et al., 2004;
Ishrat et al., 2006; Bentinger et al., 2010; Yang et al., 2008, 2010).
Minocycline, a second-generation tetracycline antibiotic
capable of inhibiting caspase-1 and -3 activities, release of
apoptogenic factors from mitochondria, as well as caspase
independent neuronal cell death pathways (Wang et al., 2003a;
Choi et al., 2007). It also suppress microglial activated production
of IL-1β, IL-6, TNF-α, and NGF (Lenaz et al., 1998; Wang et al.,
2003a,b; Ryu et al., 2004; Seabrook et al., 2006; Maier et al., 2007;
Kim and Suh, 2009). Besides, neuroprotective eﬀects has been
well documented in several neurological conditions (Seabrook
et al., 2006; Kim and Suh, 2009). Being lipophilic in nature, it
easily crosses the blood brain barrier (BBB), in order to produce
a neuroprotective eﬀect (Rauscher et al., 2001; Ryu et al., 2004).
The neuroprotective eﬀect of both CoQ10 and minocycline
have been well demonstrated in the various experimental
models of neurodegenerative disorders. In the present study, we
investigated whether administration of minocycline along with
CoQ10 exerts enhanced beneﬁcial eﬀects in the Aβ (1-42) model
of AD.
MATERIALS AND METHODS
Animals
Adult male Sprague–Dawley rats (180–200 g) from Central
Animal House of the Panjab University, Chandigarh, were used.
Animals were acclimatized to laboratory conditions prior to
experimentation at room temperature. The animals were kept
under standard conditions of 12 h light and dark cycle with
food and water ad libitum. All the experiments were carried out
between 09:00 and 15:00 h. The protocol was approved by the
Institutional Animal Ethics Committee (IAEC/411, 11/9/2013)
and carried out in accordance with the guidelines of Committee
for Control and Supervision of Experimentation on Animals
(CPCSEAs), Government of India on animal experimentation.
In our study, male animals were used because in female estrogen
hormones have been found to interfere with the memory.
Surgery and Intrahippocampal
Administration of Aβ (1-42)
Surgery was performed with procedure as described by Prakash
and Kumar (2014). Animals were anesthetized with thiopental
sodium (45 mg/kg, i.p.), head was positioned in a stereotaxic
apparatus and skull was exposed. A midline sagittal incision was
made in the scalp and two holes were drilled in the skull. The
stereotaxic coordinates for hippocampal region were 2.00 mm
posterior to bregma, 1.5 mm lateral to the sagittal suture and
1.0 mm beneath the cortical surface set according to rat brain
atlas (Paxinos and Watson, 1986). Through a skull hole, a 28-
gage Hamilton micro syringe of 10 μl units and piston of the
syringe was lowered manually into each hippocampal region.
Rats were infused intrahippocampally (i.h.) with either artiﬁcial
cerebrospinal ﬂuid (ACSF; in mmol/L: 147 NaCl, 2.9 KCl, 1.6
MgCl2, 1.7 CaCl2, and 2.2 dextrose) or Aβ (1-42) (1 μg/μl)
(CAS No. SCP0038) dissolved in ACSF according to the methods
described by Christensen et al. (2008) and Zhong et al. (2009). Aβ
(1-42) and ACSFwas administered 4μL/ site by using aHamilton
micro syringe positioned in the stereotaxic apparatus. The scalp
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was then closed with a suture. After surgery, all animals received
gentamicin (5 mg/kg, i.p.) to prevent sepsis. In sham group,
surgery was identical and animal received the same volume of
ACSF instead of Aβ (1-42). Further, it was left in place for a period
of 2 min following, i.h., administration of Aβ (1-42) to promote
its diﬀusion from the micro syringe. Special care of the animals
was taken during the post-operative period.
Drugs and Treatment Schedule
Aβ (1-42) and Galantamine (Gala) were purchased from Sigma
Chemicals, Pvt. Ltd., India. Coenzyme Q10 (CoQ10) was
purchased from Himedia Laboratories, Pvt. Ltd., India and
Minocycline was purchased from Ranbaxy Laboratories, Pvt.,
India. For drug administration Gala, CoQ10 and minocycline
were suspended in 0.25% w/v sodium-carboxy-methyl-cellulose
(Na-CMC) and administered in the dose of 5 ml/kg body weight
for 21 days. Animals were selected randomly and divided on
the basis of their body weights into several groups (n = 12
animals in each group) shown in Table 1. Doses of CoQ10 and
minocycline were selected from the previous studies (Rauscher
et al., 2001; Kalonia et al., 2012; Prakash and Kumar, 2014). Study
was performed as shown in experimental protocol (Figure 1).
Behavioral Parameters
Assessment of Cognitive Performance (Morris Water
Maze Task)
Individual animals were tested in a spatial version of the Morris
water maze (MWM) test (Morris, 1984; Kumar et al., 2007). The
apparatus consisted of a circular water tank (150 cm diameter,
40 cm high, ﬁlled to a depth of 30 cm with water at 28 ± 1◦C).
A platform (4.5 cm diameter) was placed in one quadrant of the
pool, 1 cm above the water level during the acquisition phase. The
same platform was placed 1 cm below the water level for retention
phase. The tank was located in a large room where there were
TABLE 1 | Treatment groups.
S. No. Group name Treatment (mg/kg)
(1) Naïve Healthy animals
(2) Sham Surgery performed, ACSF administered (i.h.)
(4 μl/site)
(3) Aβ (1-42) Single bilateral, i.h., Aβ (1-42) (1 μg/μl) [4 μl/site
administered]
(4) Gala (2) Galantamine (2) administered in A (1-42) treated
animals for 21 days
(5) CoQ10 (20) CoQ 10 (20) administered in Aβ (1-42) treated
animals for 21 days
(6) CoQ10 (40) CoQ 10 (40) administered in Aβ (1-42) treated
animals for 21 days
(7) Mino (50) Minocycline (50) administered in Aβ (1-42) treated
animals for 21 days
(8) Mino (100) Minocycline (100) administered in Aβ (1-42)
treated animals for 21 days
(9) CoQ10 (20) +
Mino (50)
CoQ 10 (20) + Minocycline (50) administered in
Aβ (1-42) treated animals for 21 days
(10) CoQ10 (40) +
Mino (100)
CoQ 10 (40) + Minocycline (100) administered in
Aβ (1-42) treated animals for 21 days
several brightly colored clues external to the maze; these were
visible from the pool and could be used by the rats for spatial
orientation. During each trial, the position of the clues remained
unchanged throughout the study and animal was subjected to
four consecutive trials with a gap of 5 min. The animal was gently
placed in the water of the pool between quadrants, facing the wall
of the pool which was changed with each trial, and allowed 120 s
to locate the platform. Then, animals were guided to remain on
the platform for 20 s. If animal failed to reach the platform within
120 s, the same was guided to reach the platform and remained
there for next 20 s.
Acquisition phase (training)
Animals received daily four consecutive training sessions from
day 17 to 20. During the acquisition phase, each rat was put into
the water in any one of four starting positions, the sequence of
which was selected randomly. The time latency to reach the visual
platform for escaping from water known as initial acquisition
latency (IAL) also known as escape latency time (ELT) was
measured.
Retention phase
After 24 h, i.e., on day 21 after IAL, the animal was released
randomly at one of the edges facing the wall of the pool to
assess for memory retention. Time taken by animal to ﬁnd the
hidden platform on day 21 following the start of Aβ (1-42)
administration was recorded and termed as retention latency
(RL) and time spent in the target quadrant (TSTQ) was also
recorded.
Assessment of Locomotor Activity/Closed Field
Activity
Locomotor activity was measured to rule out the interference of
change in locomotor activity in the parameters of learning and
memory. Each animal was placed in a square (30 cm) closed
arena equipped with infra-red light sensitive photocells (digital
actophotometer, IMCORP, India) and values expressed as counts
per 5 min (Galpern and Cudkowicz, 2007; Kumar et al., 2007).
Biochemical Analysis
The ﬁrst set of animals (n = 5) were used for biochemical
estimations including TNF-α levels. Biochemical tests were
conducted after last behavioral test. Animals were killed by
decapitation and their brains were taken out quickly to dissect
hippocampus and cerebral cortex (Prakash and Kumar, 2014).
The dissected brain parts were harvested and rinsed with ice-
cold isotonic saline. Brains were then homogenized with ice-
cold 0.1 mmol/l phosphate buﬀer (pH 7.4). The homogenate
(10% w/v) was then centrifuged at 10,000 g for 15 min and the
supernatant so formed was used for the biochemical estimations.
Measurement of Lipid Peroxidation
The extent of lipid peroxidation (LPO) in the hippocampus
and cortex was determined quantitatively. The thiobarbituric
acid reactive substances (TBARS) were measured at 532 nm
using Perkin Elmer Lambda 20 Spectrophotometer (Norwalk,
CT, USA) as per the method described by Wills (1966). The
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FIGURE 1 | Experimental Protocol (Aβ, amyloid beta; Gala, Galantamine; CoQ10, Coenzyme Q10; Mino, Minocycline; MWM, Morris water maze; IAL,
initial acquired latency; RL, retention latency; AChE, acetylcholinesterase; TNF, Tumor Necrosis Factor).
values were calculated using the molar extinction co-eﬃcient of
chromophore (1.56 × 105 (mol/l)−1 cm−1).
Estimation of Reduced Glutathione Levels
Reduced glutathione (GSH) was estimated according to the
method as described by Ellman (1959). The yellow color
developed was measured at 412 nm using Perkin Elmer
Lambda 20 spectrophotometer. The results were calculated using
molar extinction co-eﬃcient of the chromophore (1.36 × 104
(mol/l)−1 cm−1).
Estimation of Nitrite
The accumulation of nitrite in the supernatant, an indicator
of the production of nitric oxide (NO) was determined by
a colorimetric assay with Greiss reagent (Green et al., 1982).
The absorbance was measured at 540 nm using Perkin Elmer
Lambda 20 spectrophotometer. The concentration of nitrite in
the supernatant was determined from sodium nitrite standard
curve.
Superoxide Dismutase Activity
Superoxide dismutase (SOD) activity was assayed by the method
of Kono (1978). The change in absorbance was recorded for
2 min at 30 s intervals by measuring absorbance at 560 nm using
Perkin Elmer Lambda 20 spectrophotometer.
Catalase Activity
Catalase activity was assessed by the method of Luck (1965). The
change in absorbance was recorded for 2 min at 30 s interval
at 240 nm using Perkin Elmer Lambda 20 spectrophotometer.
The results were expressed as micromoles of hydrogen peroxide
decomposed/min/mg of protein.
Acetylcholinesterase (AChE) Activity
The AChE activity was assessed by Ellman et al. (1961). The
change in absorbance was measured for 2 min at 30 s interval at
412 nm using the Perkin-Elmer Lambda 20 spectrophotometer.
Results were expressed as micromoles of acetylthiocholine iodide
hydrolyzed/min/mg of protein.
Protein Content Estimation
The protein content was estimated by Biuret (Gornall et al., 1949)
using bovine serum albumin as a standard.
Mitochondrial Complex Estimation
Isolation of Rat Brain (Cortex and Hippocampus)
Mitochondria for Enzyme Complex Assay
Second set of animals (n = 5) was used for mitochondrial
complex estimation. The cortex and hippocampus was
homogenized in an isolation buﬀer with EGTA (215 mM
Mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 mM
EGTA, pH-7.2). Homogenates were centrifuged at 13,000 g
for 5 min at 4◦C. Pellets were resuspended in isolation buﬀer
with EGTA and spun again at 13,000 g for 5 min. The resulting
supernatants were transferred to new tubes and topped oﬀ
with isolation buﬀer with EGTA and again spun at 13,000g for
10 min. Pellets containing pure mitochondria were resuspended
in isolation buﬀer without EGTA (Berman and Hastings,
1999).
Nicotinamide Adenine Dinucleotide (NADH)
Dehydrogenase Activity
Complex-I was measured spectrophotometrically by the method
of King and Howard (1967). The method involves catalytic
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FIGURE 2 | (A) Effect of CoQ10 and minocycline alone and in combination on memory performance in Morris water maze acquisition phase in Aβ (1-42) treated
rats. Data expressed as mean ± SEM aP < 0.05 compared to sham group, bP < 0.05 compared to Aβ (1-42) treated group, cP < 0.05 compared to CoQ10 (20)
group, dP < 0.05 compared to Mino (50) group, eP < 0.05 compared to CoQ10 (40); fP < 0.05 compared to Mino (100) group (Two way ANOVA followed by
Bonferroni’s t-test). (B) Effect of CoQ10 and minocycline alone and in combination on time spent in the target quadrant (TSTQ) in the Morris maze retention phase
(21st day) in Aβ (1-42) treated rats. Data expressed as mean ± SEM aP < 0.05 compared to sham group, bP < 0.05 compared to Aβ (1-42) treated group,
cP < 0.05 compared to CoQ10 (20) group, dP < 0.05 compared to Mino (50) group, eP < 0.05 compared to CoQ10 (40), fP < 0.05 compared to Mino (100) group
(One way ANOVA followed by Tukey’s test). (Aβ, Amyloid beta; Gala, Galantamine; CoQ10, Coenzyme Q 10; Mino, Minocycline).
FIGURE 3 | Effect of CoQ10 and minocycline alone and in combination on locomotor activity (ambulation) in Aβ (1-42) treated rats. Data expressed as
mean ± SEM (Two way ANOVA followed by Bonferroni’s test). (Aβ (1-42), Amyloid beta; Gala, Galantamine; CoQ10, Coenzyme Q 10; Mino, Minocycline).
oxidation of NADH to NAD+ with subsequent reduction in
cytochrome C. The reaction was initiated by addition of requisite
amount of solubilized mitochondrial sample and followed by an
absorbance change at 550 nm for 2 min.
Succinate Dehydrogenase (SDH) Activity
Succinate Dehydrogenase (SDH) was measured
spectrophotometrically according to King (1967). The method
involves oxidation of succinate by an artiﬁcial electron acceptor,
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TABLE 2 | Effect of CoQ10 and minocycline on oxidative stress parameters in Aβ (1-42) treated animals.
Treatment
group
(mg/kg)
Brain Region LPO (nmol MDA/mg of
protein) (% of Sham)
Nitrite (μmol/mg of
protein) (% of Sham)
GSH (nmol of GSH/mg
Pr) (% of Sham)
Catalase (μM of
H2O2/min/mgpr) (%
of Sham)
SOD (Units/mg of
protein) (% of Sham)
Naïve Cortex
Hippocampus
0.0184 ± 0.6 (97)
0.0246 ± 0.3 (95)
239.6 ± 2.1 (101)
181.8 ± 4.5 (98)
0.61 ± 0.02 (105.1)
0.69 ± 0.08 (97.1)
7.36 ± 0.52 (105.2)
6.22 ± 0.08 (101)
0.49 ± 0.017 (102.8)
0.593 ± 0.02 (106.0)
Sham (ACSF) Cortex
Hippocampus
0.019 ± 0.88 (100)
0.0259 ± 0.01(100)
237.3 ± 1.4 (100)
285.6 ± 2.18 (100)
0.58 ± 0.02 (100)
0.71 ± 0.03 (100)
7 ± 0.25 (100)
6.16 ± 0.32 (100)
0.48 ± 0.04 (100)
0.56 ± 0.02 (100)
Aβ (1-42)
(1 μg/μl)
Cortex
Hippocampus
0.0912 ± 0.3a (480)
0.134 ± 0.25a (520)
643.08 ± 2.09a (341.4)
828.2 ± 2.60a (290.7)
0.239 ± 0.21a (41.3)
0.238 ± 0.08a (33.6)
2 ± 0.05a (28.5)
2.20 ± 0.12a (35.8)
0.103 ± 0.0012a (21.5)
0.164 ± 0.88a (29.4)
Gala (2) Cortex
Hippocampus
0.0221 ± 0.32b (116.8)
0.0318 ± 0.65b (122.8)
285.5 ± 7.5b (119.9)
295.8 ± 2.84b (103.6)
0.49 ± 0.02b (89)
0.673 ± 0.03b (94.9)
6.559 ± 0.24b (93.7)
5.69 ± 0.15b (92.5)
0.449 ± 0.23b (93.7)
0.505 ± 0.21b (90.3)
CoQ 10 (20) Cortex
Hippocampus
0.0699 ± 0.1b (368.42)
0.107 ± 0.13b (416.77)
611.7 ± 1.64b (257.8)
760.8 ± 6.42b (266.4)
0.103 ± 0.01b (47.7)
0.096 ± 0.21b (43.5)
2.73 ± 0.16b (39
2.5 ± 0.17b (40.5)
0.172 ± 0.2b (36.04)
0.239 ± 0.02 b (42.8)
CoQ 10 (40) Cortex
Hippocampus
0.028 ± 0.25b,c (152.6)
0.053 ± 0.1b,c (208)
447.7 ± 6.17b,c (188.7)
430.1 ± 4.17b,c (150.6)
0.406 ± 0.18b,c (70)
0.503 ± 0.03b,c (70.8)
3.31 ± 0.10b,c (47.4)
4.27 ± 0.04b,c (69.4)
0.201 ± 0.11b,c (42)
0.305 ± 0.28b,c (54.6)
Mino (50) Cortex
Hippocampus
0.0589 ± 0.31b (310)
0.086 ± 0.13b (333.9)
333.3 ± 9.27b (240.4)
432.6 ± 12.8b (249)
0.346 ± 0.34 b (59.8)
0.440 ± 0.52b (62.1)
2.205 ± 0.38b (31.5)
3.22 ± 0.46b (52.43)
0.109 ± 0.04b (22.9)
0.149 ± 0.26 b (26.7)
Mino (100) Cortex
Hippocampus
0.0329 ± 0.16b (173.6)
0.0482 ± 0.9b (186.4)
451.5 ± 4.16b (190.3)
497.2 ± 18.5b (174.1)
0.428 ± 0.30b (73.9)
0.492 ± 0.25b (69.3)
3.36 ± 0.41b (48.1)
3.82 ± 0.52b (62.1)
0.209 ± 0.6b (43.7)
0.359 ± 0.45b (64.2)
CoQ10 (20) +
Mino (50)
Cortex
Hippocampus
0.0401 ± 0.5b,c,d (211.5)
0.0699 ± 0.2b,c,d (270.2)
463.4 ± 2.9b,c,d (195.3)
621.7 ± 1.9b,c,d (217.7)
0.454 ± 0.17b,c,d (78.3)
0.511 ± 0.2b,c,d (72.1)
3.5 ± 0.3b,c,d (50)
4.8 ± 0.23b,c,d (77.9)
0.289 ± 0.3b,c,d (60.4)
0.409 ± 0.5b,c,d (73.2)
CoQ10 (40) +
Mino(100)
Cortex
Hippocampus
0.0230 ± 0.8b,e,f (121.5)
0.0372 ± 0.23b,e,f (144)
305.8 ± 12.4b,e,f (128.9)
378.9 ± 3.17b,e,f (132.7)
0.498 ± 0.9b,e,f (86)
0.646 ± 0.3b,e,f (91)
6.02 ± 0.84b,e,f (86.1)
5.62 ± 0.15b,e,f (91.3)
0.42 ± 0.40b,e,f (88.6)
0.49 ± 0.15b,e,f (87.7)
Values are mean ± SEM.
aP < 0.05 compared to sham group, bP < 0.05 compared to Aβ (1-42) treated group, cP < 0.05 compared to CoQ10 (20) group, dP < 0.05 compared to Mino (50)
group,eP < 0.05 compared to CoQ10 (40), fP < 0.05 compared to Mino (100) group (One way ANOVA followed by Tukey’s test). (Aβ, Amyloid beta; Gala, Galantamine;
CoQ10, Coenzyme Q 10; Mino, Minocycline).
potassium ferricyanide. The reaction was initiated by the
addition of mitochondrial sample and absorbance change was
followed at 420 nm for 2 min.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
(MTT) Assay
Also known as mitochondrial redox activity assay, this method
is based on the in vitro studies to evaluate mitochondrial redox
activity through the conversion of MTT tetrazolium salt to
formazan crystals by mitochondrial respiratory chain reactions
in isolated mitochondria by the method of Liu et al. (1997). The
absorbance of the resulting medium was measured by an ELISA
reader at 580 nm wavelength.
Cytochrome Oxidase Activity
Cytochrome oxidase activity was assayed in brain mitochondria
according to the method of Sotocassa et al. (1967). The reaction
was started by the addition of solubilized mitochondrial sample
and absorbance change was recorded at 550 nm for 2 min.
Estimation of TNF-α Activity
The same ﬁrst set of animals was used for the estimation of TNF-
α level in rat brain. The quantiﬁcation of cytokine TNF-α was
performed as per the instruction of R&D Systems Quantikine
rat TNF-α immunoassay kit (R&D Systems, Minneapolis, MN,
USA). The Quantikine rat TNF-α immunoassays is 4.5 h solid
phase ELISA designed to measure rat TNF-α level. Brieﬂy, the
assays employ the sandwich enzyme immunoassay technique
(Prakash and Kumar, 2014). Monoclonal antibody speciﬁc for
rat TNF-α have been pre-coated in the micro plate. Standards,
control, and samples are pipette into the wells and any rat-TNF-α
present is bound by the immobilized antibody. After washing
away any unbound substance an enzyme linked polyclonal
antibody speciﬁc for rat TNF-α was added to the wells.
Following a wash to remove any unbound antibody-enzyme
reagent, a substrate solution is added to the wells. The enzyme
reaction yields a blue product that turns yellow when the
stop solution is added. The intensity of the color measured
is in proportion to the amount of rat TNF-α bound in the
initial steps. The sample values are then read oﬀ the standard
curve.
Histopathological Analysis by
Hematoxylin and Eosin Staining (H and E
Staining)
The remaining third set of animals was used for histopathological
analysis. Animals were sacriﬁced by decapitation immediately
after the last behavioral test (Prakash and Kumar, 2014).
The brains were removed and transferred to formalin (10%
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FIGURE 4 | Effect of CoQ10 and minocycline alone and in combination on mitochondrial respiratory enzymes in the hippocampus and cortex region
of Aβ (1-42) treated rats. Data expressed as mean ± SEM aP < 0.05 compared to sham group; bP < 0.05 compared to Aβ (1-42) treated group; cP < 0.05
compared to CoQ10 (20) group; dP < 0.05 compared to Mino (50) group; eP < 0.05 compared to CoQ10 (40); fP < 0.05 compared to Mino (100) group (One way
ANOVA followed by Tukey’s test). (Aβ, Amyloid beta; Gala, Galantamine; CoQ10, Coenzyme Q 10; Mino, Minocycline).
FIGURE 5 | Effect of CoQ10 and minocycline alone and in combination on AChE activity in the hippocampus and cortex region of Aβ (1-42) treated
rats. Data expressed as mean ± SEM aP < 0.05 compared to sham group; bP < 0.05 compared to Aβ (1-42) treated group; cP < 0.05 compared to CoQ10 (20)
group; dP < 0.05 compared to Mino (50) group; eP < 0.05 compared to CoQ10 (40); fP < 0.05 compared to Mino (100) group (One way ANOVA followed by
Tukey’s test). (Aβ, Amyloid beta; Gala, Galantamine; CoQ10, Coenzyme Q 10; Mino, Minocycline; AChE, acetylcholinesterase).
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FIGURE 6 | Effect of CoQ10 and minocycline alone and in combination on TNF-α level in Aβ (1-42) treated rats. Data expressed as mean ± SEM,
aP < 0.05 compared to sham group, bP < 0.05 compared to Aβ (1-42) treated group, cP < 0.05 compared to CoQ10 (20) group, dP < 0.05 compared to Mino (50)
group, eP < 0.05 compared to CoQ10 (40), fP < 0.05 compared to Mino (100) group (One way ANOVA followed by Tukey’s test). (Aβ, Amyloid beta; Gala,
Galantamine; CoQ10, Coenzyme Q 10; Mino, Minocycline).
v/v). The brain tissues were embedded in paraﬃn blocks
and sectioned into 3 mm thickness with the help of a
microtome. The brain sections (5–10 μm) thick were de-
waxed and stained with hematoxylin and eosin. Brieﬂy,
sections were immersed in the ﬁltered hematoxylin solution
for 1 min followed by rinsing with tap water. Then, the
sections were immersed in eosin stain for 1–2 min and
rinsed thoroughly with tap water followed by dehydration
in ascending alcohol solutions (50, 70, 80, 95, and 100%).
Now the sections were mounted on labeled slides. The
stained sections were viewed under a binocular microscope
(Nikon Eclipse 80i, Nikon Instruments Inc., USA) at 40×
for evaluating the hippocampal regions of the brain for
morphological changes and photographed (Galpern and
Cudkowicz, 2007). The particular hippocampal areas were
analyzed for the presence and density of pyknotic nuclei. The
number of such pynotic nuclei per square pixel were analyzed
using computer based image analysis (Image J 1.42q, NIH,
USA).
Statistical Analysis
Graph Pad Prism (Graph Pad Software, San Diego, CA, USA)
was used for all statistical analysis. Values are expressed as
mean ± SEM. The behavioral assessment data were analyzed
by a repeated measures two-way analysis of variance (ANOVA)
with drug-treated groups as between sessions and as within-
subjects factors. The biochemical estimations were analyzed
by one-way ANOVA. Post hoc comparisons between groups
were made using Tukey’s test. The P < 0.05 was considered
signiﬁcant.
RESULTS
Effect of CoQ10, Minocycline and Their
Combinations on Spatial Navigation Task
on Morris Water Maze in Aβ (1-42)
Treated Animals
Sham treated animals did not produce any signiﬁcant eﬀect on
memory performance inMWMtest as compared to a naïve group
of animals. However, Aβ (1-42) treatment signiﬁcantly caused
a downward trend in ELT on subsequent water-maze exposure
during training session (from day 17 to 20) as compared to
the sham group indicating poor learning performance. Chronic
treatment with CoQ10 (20 and 40 mg/kg), and minocycline
(50 and 100 mg/kg) signiﬁcantly (P < 0.05) improved memory
performance and shortened escape latency as compared to Aβ
(1-42) treated group. Further, treatment of CoQ10 (20 and
40 mg/kg) in combination with minocycline (50 and 100 mg/kg)
signiﬁcantly improved cognitive performance as compared to
their eﬀect per se in Aβ (1-42) treated animals. Their protective
eﬀect was comparable to that of Gala (2 mg/kg) treatment in Aβ
(1-42) treated animals (Figure 2A).
Sham treatment did not produce any signiﬁcant eﬀect on the
time spent in the target quadrant (TSTQ) as compared to naïve
animals. Aβ (1-42) treated animals performed poorly and failed
to recollect the location of the submerged platform on the 21st
day, thus spending signiﬁcantly less time in the target quadrant
as compared to the sham group. However, CoQ10 (20 and
40 mg/kg), and minocycline (50 and 100 mg/kg) treatment for
21 days signiﬁcantly increased TSTQ as compared to Aβ (1-42)
treated group. Further, treatment of CoQ10 (20 and 40 mg/kg) in
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FIGURE 7 | Histopathological sections of rat brain stained with Hematoxylin and Eosin stain (H and E). Representative photomicrographs of CA regions of
hippocampus sections (magnification 10X, from A–G) of rat. (A) Sham: neurons are intact; (B) Aβ (1-42): inflammatory cells; (C) Gala (2): mild inflammation of
neurons; (D) CoQ10 (20): moderate inflammation of neurons; (E) CoQ10 (40): moderate inflammation of neurons; (F) CoQ10 (20) + Minocycline (50): moderate
inflammation of neurons; (G) CoQ10 (40) + Minocycline (100): mild inflammation of neurons (as shown by the arrow).
combination with minocycline (50 and 100 mg/kg) signiﬁcantly
(p < 0.05) improved cognitive performance (increased TSTQ)
as compared to their eﬀect per se in Aβ (1-42) treated animals.
Their protective eﬀect was comparable to that of Gala (2 mg/kg)
treatment in Aβ (1-42) treated animals (Figure 2B).
Effect of CoQ10, Minocycline and Their
Combinations on Locomotor Activity in
Aβ (1-42) Treated Animals
Locomotor activity in all groups was almost same before the start
of surgery. However, there is no signiﬁcant eﬀect in mean scores
of locomotor activity between naïve, sham treated and Aβ (1-
42) treated animals. Chronic administration of CoQ10 (20 and
40 mg/kg) and minocycline (50 and 100 mg/kg) did not produce
any signiﬁcant eﬀect on the locomotor activity as compared to
Aβ (1-42) treated group. Further, combination of CoQ10 (20 and
40 mg/kg) with minocycline (50 and 100 mg/kg) in Aβ (1-42)
treated animals did not produce any eﬀect on locomotor activity
on 7th, 14th, and 21st day as compared to Aβ (1-42) treated
animals (Figure 3).
Effect of CoQ10, Minocycline and Their
Combinations on Oxidative Stress
Parameters in Aβ (1-42) Treated Animals
Single bilateral, i.h., Aβ (1-42) administration caused signiﬁcant
rise in LPO, nitrite concentration and depletion of reduced
GSH, SOD and catalase levels in hippocampus and cortex as
compared to sham group. However, chronic CoQ10 (20 and
40 mg/kg) and minocycline (50 and 100 mg/kg) administration
signiﬁcantly (p < 0.05) attenuated oxidative stress (reduced
the elevated MDA, nitrite concentration and restored SOD,
catalase and GSH levels), as compared to Aβ (1-42) treated
animals (P < 0.01). Further, treatment of CoQ10 (20 and
40 mg/kg) in combination with minocycline (50 and 100 mg/kg)
signiﬁcantly (0.05) potentiated their protective eﬀect as
compared to their eﬀects alone in Aβ (1-42) treated animals.
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FIGURE 8 | Graph showing the effect of CoQ10 and Minocycline on pyknotic expressions per square pixel. Data expressed as mean ± SEM, aP < 0.05
compared to sham group, bP < 0.05 compared to Aβ (1-42) treated group, cP < 0.05 compared to CoQ10 (20) group, dP < 0.05 compared to CoQ10 (20) group
and Aβ (1-42) treated group, eP < 0.05 compared to CoQ10 (40) and Aβ (1-42) treated group (One way ANOVA followed by Tukey’s test). (Aβ, Amyloid beta; Gala,
Galantamine; CoQ10, Coenzyme Q 10; Mino, Minocycline).
Eventually, their protective eﬀect was comparable to that of Gala
(2 mg/kg) treatment in Aβ (1-42) treated animals (P < 0.05)
(Table 2).
Effect of CoQ10, Minocycline and Their
Combinations on Mitochondrial Enzyme
Complex in Aβ (1-42) Treated Animals
Mitochondrial enzyme complex (NADH dehydrogenase,
succinate dehydrogenase and cytochrome oxidase and cell
viabilities activities) signiﬁcantly depleted in hippocampus
and cortex regions of Aβ (1-42) treated group as compared
to sham group (P < 0.05). However, chronic CoQ10 (20 and
40 mg/kg) and minocycline (50 and 100 mg/kg) treatment
signiﬁcantly restored mitochondrial enzymes complex activities
and increased cell viability as compared to Aβ (1-42) treated
animals (P < 0.05). Further, treatment of CoQ10 (20 and
40 mg/kg) in combination with minocycline (50 and 100 mg/kg)
signiﬁcantly (P < 0.05) potentiated their protective eﬀect which
was signiﬁcant (P < 0.05) in comparison with their eﬀects alone
in Aβ (1-42) treated animals. As expected, their protective eﬀect
was comparable to that of Gala (2 mg/kg) treatment in Aβ (1-42)
treated animals (P < 0.05) (Figure 4).
Effect of CoQ10, Minocycline and Their
Combinations on AChE Activity in Aβ
(1-42) Treated Animals
Single bilateral, i.h, Aβ (1-42) treatment signiﬁcantly increased
AChE activity in hippocampus and cortex regions as compared
to the sham group (P < 0.05). However, treatment with CoQ10
(20 and 40 mg/kg) and minocycline (50 and 100 mg/kg) for
21 days signiﬁcantly (P < 0.05) attenuated AChE activity which
was signiﬁcant as compared to Aβ (1-42) treated animals.
Further, treatment of CoQ10 (20 and 40 mg/kg) in combination
with minocycline (50 and 100 mg/kg) for 21 days signiﬁcantly
(P < 0.05) potentiate their protective eﬀect in Aβ (1-42) treated
animals. Finally, their protective eﬀect was comparable to that of
Gala (2 mg/kg) treatment in Aβ (1-42) treated animals (Figure 5).
Effect of CoQ10, Minocycline and Their
Combinations on Brain Hippocampus
(TNF-α) Level in Aβ (1-42) Treated
Animals
Single bilateral, i.h., Aβ (1-42) administration signiﬁcantly
elevated TNF-α level as compared to sham group. Chronic
CoQ10 (20 and 40 mg/kg) and minocycline (50 and 100 mg/kg)
administration signiﬁcantly attenuated TNF-α level (P < 0.05)
in the hippocampus region of Aβ (1-42) treated animals
which was signiﬁcant as compared to Aβ (1-42) treated
group (P < 0.05). Further, treatment of CoQ10 (20 and
40 mg/kg) in combination with minocycline (50 and 100 mg/kg)
signiﬁcantly potentiated their protective eﬀect in Aβ (1-42)
treated animals. Their protective eﬀect was comparable to that
of Gala (2 mg/kg) treatment in Aβ (1-42) treated animals
(Figure 6).
Histopathological Examination
Histopathological evaluation of brain tissue was carried on under
light microscopy. Brain sections for the diﬀerent groups of animal
are shown in Figure 7. In the histopathological study, sham-
treated brain showed undamaged neuronal cells as compared
to naïve animal. However, disarrangement of various cell layers
as well as the pyramidal neuronal cell loss and increase in the
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FIGURE 9 | Schematic diagram showing the mechanism of action of CoQ10 and Minocycline (CoQ10, coenzyme Q10; Minocycline, minocycline;
AChE, acetylcholinesterase; Cyt. C, cytochrome c).
density of pyknotic cells (number of pyknotic cells, per 128800
square pixels of area; representing inﬂammation) were found in
CA1 and CA3 hippocampal regions of brain in Aβ (1-42) treated
animals which was signiﬁcant as compared to sham group. At
some places, cortical spongiosis was also observed in the brains
of Aβ (1-42) treated animals. However, 21 days chronic CoQ10
(20 and 40 mg/kg) and minocycline (50 mg/kg) administration
signiﬁcantly attenuated the loss of neuronal cell density and
reduction in the number of pyknotic cells as compared to Aβ
(1-42) treated animals. Moreover, the neuroprotective eﬀects of
CoQ10 (20 and 40 mg/kg) were potentiated dose dependently
by the combination of minocycline (50 and 100 mg/kg) where
the integrity of the neuronal cell layer and reduced number of
pyknotic cells displayed less neuroinﬂammation as compared to
their eﬀect alone. Their protective eﬀect was comparable to that of
Gala (2 mg/kg) treatment in Aβ (1-42) treated animals (P < 0.05)
(Figure 8)
DISCUSSION
Alzheimer’s disease is a slow, progressive neurodegenerative
problem with unknown etiology. It is a leading cause of senile
dementia characterized by neuronal degeneration, cognitive
dysfunction. Several mechanisms have been suggested to
explain its complex pathophysiology particularly oxidative
stress, neuroinﬂammation, mitochondrial dysfunction and
apoptosis (Hampel et al., 2011; Braak and Del Tredici, 2012;
Anand et al., 2014; Association, 2014; Kumar and Singh,
2015).
In our study, i.h., administration of Aβ (1-42) signiﬁcantly
impaired cognitive performance in MWM test as indicated
by delayed transfer latency time to reach the platform
(ELT) and shortened TSTQ as compared to sham group,
suggesting that Aβ (1-42) induced impairment in spatial
learning and memory. It also causes signiﬁcant increase
in AChE activity supporting an impairment of the
cholinergic system, suggesting Aβ (1-42) causes cholinergic
dysfunction. The ﬁndings of the present study revealed that,
i.h., administration of Aβ (1-42) resulted in a signiﬁcant
increase in MDA; nitrite concentration, depleted reduced
glutathione, SOD and catalase activities in Aβ (1-42) treated
animals suggesting oxidative stress. The present study also
indicated that, i.h., Aβ (1-42) accumulation signiﬁcantly
altered the activity of mitochondrial respiratory enzymes
(NADH dehydrogenase, succinate dehydrogenase activity,
cytochrome C oxidase) and impaired the neural cell
viability of Aβ (1-42) treated animals as compared to sham
treated animals suggesting mitochondrial dysfunction. In
this study, i.h., administration of Aβ (1-42) signiﬁcantly
increased TNF-α level in Aβ (1-42) treated animals as
compared to sham treated animals, indicating the role
of neuroinﬂammation in Aβ (1-42) model of cognitive
dysfunction.
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Previous studies have also demonstrated the neuroprotective
potential of both CoQ10 and minocycline in diﬀerent
neurological conditions (Rauscher et al., 2001; Beal, 2004;
Ryu et al., 2004; Turunen et al., 2004; Somayajulu et al.,
2005; Seabrook et al., 2006; Kim and Suh, 2009). However,
their mechanism of action is not yet clear. Supporting to the
above, the present study demonstrated the neuroprotective
eﬀect of CoQ10 and minocycline against Aβ (1-42) induced
cognitive dysfunction. Therefore, beneﬁcial treatment of
CoQ10 along with minocycline in neurodegenerative disorders
including AD with multiple pathogenic properties can be
achieved through drugs targeting multiple pathways or
polytherapeutic interventions directed toward speciﬁc aspect
of the neurodegenerative phenotype (Kumar and Singh,
2015).
Coenzyme Q10 is a well known lipophilic antioxidant
compound, has been reported to improve cognitive function, up
regulates mitochondrial function and facilitates ATP synthesis
(Ishrat et al., 2006; Hargreaves, 2014). Supplementation of
CoQ10 increases brain endogenous Q10 content and aﬀords
as an antioxidant against free radical generation as well as
oxidative modiﬁcation of biomolecules (Ishrat et al., 2006;
Hargreaves, 2014). It also provides signiﬁcant improvement
in patients with neurological disorders (Moreira et al., 2005;
Ishrat et al., 2006; Stack et al., 2006; Hargreaves, 2014).
The major role of CoQ is to transfer electrons between
redox components of the ETC, to create a proton gradient
across the inner mitochondrial membrane and drive ATP
formation and as a powerful antioxidant that has been
shown to be protective against oxidative stress (Moreira
et al., 2005; Lenaz et al., 2007). Thus, CoQ10 protects
in vivo against oxidation of lipids, proteins, and DNA.
Previous evidence has suggested an intimate link between
an excessive generation of ROS/RONS and development of
hippocampal neuronal death (Ishrat et al., 2006; Galpern and
Cudkowicz, 2007; Swomley et al., 2014). In the present study,
chronic treatment with CoQ10 (20 and 40 mg/kg) in Aβ (1-
42) treated animals signiﬁcantly attenuated an impairment
of spatial learning and memory task performance, AChE
activities, mito-oxidative damage, restored mitochondrial
respiratory enzyme complex activities and TNF-α level
suggesting its anti-oxidant, mitochondrial restoring and
anti-inﬂammatory action as compared to Aβ (1-42) treated
animals.
Minocycline, a semi-synthetic second-generation tetracycline
analog has both antimicrobial and anti-inﬂammatory activity
(Kim and Suh, 2009). It also possesses eﬃcacy against broad
range of neurological disorders with good clinical safety
record (Ryu et al., 2004; Seabrook et al., 2006; Maier et al.,
2007; Kim and Suh, 2009). Previous studies on animal model
(Smac/Diablo) have showed that minocycline prevented the
release of cytochrome c in isolated mitochondria from,
suggesting mitochondria as a direct target of minocycline
(Wang et al., 2003c). Minocycline, has also known to
inhibit the formation of Aβ aggregates and disassembles
the performed ﬁbrils (Burgos-Ramos et al., 2009). In the
present study, chronic treatment with minocycline improved
spatial learning and memory task performance, reduced AChE
activities, mito-oxidative damage, restored mitochondrial
respiratory enzyme complex activities and attenuated TNF-α
level, suggesting its anti-oxidant, mitochondrial restoring and
anti-inﬂammatory action as compared to Aβ (1-42) treated
animals.
Further, chronic treatment of CoQ10 in combination
with minocycline animals signiﬁcantly enhanced their
neuroprotective eﬀect (attenuated spatial learning and
memory performance task, AChE activities, mito-oxidative
damage, restored the mitochondrial respiratory enzyme
activities and TNF-α level) suggesting their synergistic
action. In the present study, Aβ (1-42) administration
causes signiﬁcant damage in the hippoacampal and cortical
regions of the rat brain that plays important role in
the learning and memory. For the histopathological
evaluations of the rat brains, hippocampal region were
targeted and it was observable that brain areas of Aβ
(1-42) treated animals had signiﬁcantly higher density of
pyknotic neuronal cells suggesting degeneration and disrupted
functioning of the hippocampal neurons. Besides, CoQ10 in
combination with minocycline, signiﬁcantly improved cell
layer organization, reduced density of pyknotic cells and
pyramidal cell in the CA1 and CA3 regions as compared
to their eﬀects alone in Aβ (1-42) treated rat brain
hippocampus.
CONCLUSION
In support, these results highlight anti-oxidant, anti-
inﬂammatory and mitochondrial restoring property to CoQ10
andminocycline combination. Further, their combination targets
at multiple sites in AD pathology as depicted in Figure 9. It
seems that minocycline in combination with CoQ10 signiﬁcantly
modulate their neuroprotective eﬀect against Aβ (1-42) induced
cognitive dysfunction. Study further provides a hope that this
drug combination could be used successfully in the management
of AD.
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